Medpace Holdings, Inc. (MEDP)
POSITIVEFundamental
69
Precio
$611.49
Capitalización Bursátil
$17.31B
Parte 1 · Cuánto vale la empresa
Resumen
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$2.78B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$492M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$682M
Patrimonio Neto Total
$459M
Pasivo Total
$1.52B
Ratio de Liquidez
0.73
Cobertura de Intereses
-
Deuda/EBITDA
0.24
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$847.98
Precio Actual
$611.49
Margen de Seguridad
+27.9%
Rango de Valor Justo
$551.19 - $1144.77
Métodos de Estimación
Métricas de Valoración
Ratio P/E
36.39
ROE
98.3%
Ratio P/B
39.89
P/FCF
24.49
Margen Bruto
-
ROIC
74.1%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
74.1%
WACC
10.9%
ROIC − WACC
+63.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Criterios de Análisis Fundamental
Superado (17)
- EPS shows upward trend
- Price CAGR 32.92%
- ROIC 74.1%
- P/FCF 24.49
- Debt/Equity ratio
- Operating Margin 21.0%
- Positive Free Cash Flow
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- ROE 110.1%
- Revenue Growth 5Y 22.3%
- Earnings Surprise avg 7.5%
- PEG Ratio 1.05
- Earnings Quality (OCF/NI) 1.53
- Share Dilution -7.8%
- Piotroski F-Score 6/9
Fallido (7)
- P/B Ratio 39.89
- Current Ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 35% Buy
- Net Margin Trend 17.7% vs 18.7%
No disponible (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. August James Troendle M.D. | CEO, President & Chairman | 69 |
| Mr. Kevin M. Brady | CFO & Treasurer | 50 |
| Mr. Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel & Corporate Secretary | 56 |
| Mr. Brad W. Hansman | Executive Vice President of Operations | 42 |
| Ms. Lauren Morris | Associate Director of Investors Relations | - |
| Mr. Todd Meyers | Vice President of Business Development & Marketing | - |
| Mr. Weimin Gai MS | Senior Vice President of Biometrics | - |
| Mr. John T. Wynne MBA | Chief Business Officer | - |
| Ms. Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department | 64 |
| Ms. Gina Leisring M.P.H. | Senior Vice President of Clinical Monitoring | - |
Riesgo de Auditoría
6
Riesgo del Consejo
8
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
5
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for MEDP, sourced from Markets Gazette.